Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
niix is a fitness app plugging the gap in the market for women approaching 40. Since its launch in 2018, the company has created a 4+ star rated app with more than 1800 paid subscriptions across 25 countries including the US, Canada, and Australia. It also has an online following of tens of thousands. The global fitness app market is growing fast set to be worth $2 billion by 2023 with a focus on weight loss and body aesthetics for millennial markets. niix sees a huge opportunity in this space to support women who have simply outgrown an approach that want the perfect body and be fit lifelong. With the investment, the company will scale up proven marketing channels to grow community and subscriber bases, making niix the no.1 digital fitness brand for women approaching 40+.
days to go:
Expired
investment:
£153,441
Lifetise generates proprietary consumer data via its portal to boost the Artificial Intelligence (AI) based decision-making process within banks and insurers and increase their product sales. Lifetise asserts that its portal helps financial institutions acquire and fulfil the needs of high-value customers at a lower cost to the organisation. It is in negotiations with three retail banks and is an Accenture Fintech Lab alumni. The company was named as one of the most influential financial technology entities of 2020 by The Financial Technologist magazine and selected for the Mayor of London's 'Business Growth Programme' under the 'Most high potential startups' category in 2021. Lifetise will use 58% of the investment in product development and engineering to scale its technology platform, 31% on sales and marketing, and 11% on operations.
days to go:
Expired
investment:
£369,407
Carverter is a technology platform that enables customers to find and lease a hybrid or Electric Vehicle (EV). The company cites data pointing out the UK government's ban on the sale of petrol and diesel only cars after 2030. It also argues about changing car preferences, with 78% of consumers considering leasing to access an EV. Carverter aims to capture this audience and grow its business. The company uses its algorithm to bring together over 32 million data points across its three tools, namely Carvert, Carwizard, and Browse, to help users find their choice of hybrid/EV. Carverter has partnered with renowned entities like WPP, Arval, Microsoft & ITV to boost its business. It will use 10% of the investment on hiring staff, 20% towards rolling out its services across 22 European countries via Arval, and 70% on an advertising multiplier deal with the UK's largest commercial broadcaster, ITV, and WPP.
days to go:
Expired
investment:
£2,324,693
Integumen is a personal health company developing and commercialising technology and products for the human integumentary system that may improve physical appearance, hygiene and general health outcomes.
days to go:
Expired
investment:
£2,160,000
Helping SME home builders acquire finance for their projects in the UK. Rubicon Capital has assisted more than 40 project developers in receiving investments for their builds, which has exceeded £75m. In their second year, the company generated £500k in profits and has successfully paid dividends every year since launching in 2015. Two main sources of revenue are upfront fees for connecting borrowers with lenders and administration fees in the form of long-term consultancy and performance assistance.
Money raised from this crowdfunding round will be used to expand the Rubicon Capital team and grow their business to attract more home builders requiring financial assistance, in addition to increasing the number of sources offering finance.
days to go:
Expired
investment:
£128,510
